Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 7:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,427 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetes Mellitus, Type 1 Diabetes
Interventions
AHEAD Program
Behavioral
Lead sponsor
University of British Columbia
Other
Eligibility
16 Years to 19 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Insulin Response, Type 1 Diabetes
Interventions
Standardized meal 1
Other
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 90 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
College Station, Texas
Conditions
Type 1 Diabetes Mellitus
Interventions
Humalog, Novolog, BC222 insulin lispro, Bionic Pancreas
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
ELG
Device
Lead sponsor
XP Technology, LLC
Other
Eligibility
25 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Springdale, Arkansas
Conditions
Type1 Diabetes Mellitus
Interventions
Beta Cell Loss and Immune Function, Immune Function with RNAseq
Diagnostic Test · Other
Lead sponsor
University of Exeter
Other
Eligibility
Up to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Diabetes Mellitus, Type 1
Interventions
Blood Glucose Awareness Training for Parents
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
6 Years to 11 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Completed Phase 3 Interventional Results available

Mylan Insulin Aspart Study

NCT03760068
Conditions
Diabetes Mellitus, Type 1
Interventions
MYL-1601D Product, FlexPen NovoLog®
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
158
States / cities
Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 125 more
Completed Not applicable Interventional Results available

Improving Diabetes in Emerging Adulthood

NCT04066959
Conditions
Diabetes Mellitus, Type 1
Interventions
Motivational Enhancement System (MES), Question Prompt List (QPL), Text Message Reminders (TXT)
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
16 Years to 25 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Diabetes Mellitus Type 1
Interventions
Allogeneic Pancreatic Endocrine Cell Clusters
Biological
Lead sponsor
Seraxis
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine,300 U/mL, Insulin glargine (100 units /mL), Background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 17 Years
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
13
States / cities
Tucson, Arizona • Atlanta, Georgia • Indianapolis, Indiana + 9 more
Conditions
Type 1 Diabetes
Interventions
Fit Families plus Standard Medical Care
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
10 Years to 17 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Detroit, Michigan
Completed No phase listed Observational Accepts healthy volunteers

Type 1 Diabetes and the Brain in Children

NCT02351466
Conditions
Diabetes Mellitus, Type 1
Interventions
Observational
Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
7 Years to 16 Years
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
5
States / cities
Palo Alto, California • New Haven, Connecticut • Jacksonville, Florida + 2 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose

NCT04623086
Conditions
Type 1 Diabetes
Interventions
Insulin Degludec, Insulin Glargine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Type 1 Diabetes
Interventions
Control-IQ Technology v1.5
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
2 Years to 5 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Diego, California
Completed Not applicable Interventional Results available

CGM Use in Islet Transplant Recipients

NCT03427931
Conditions
Islet Transplantation, Type1 Diabetes Mellitus
Interventions
Continuous Glucose Monitor (CGM)
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Diabetes Mellitus, Type 1
Interventions
Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 35 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
23
States / cities
Orange, California • Palo Alto, California • San Francisco, California + 20 more
Conditions
Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Metabolic Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
West Palm Beach, Florida
Conditions
Type 1 Diabetes
Interventions
Belatacept and Raptiva
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
San Francisco, California
Conditions
Type 1 Diabetes
Interventions
Resveratrol, Placebo
Drug · Other
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Terminated Phase 2 Interventional Results available

TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)

NCT00451321
Conditions
Diabetes Mellitus, Type 1
Interventions
Otelixizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 45 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
16
States / cities
Birmingham, Alabama • Walnut Creek, California • Aurora, Colorado + 13 more
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells
Biological · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 68 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Terminated Not applicable Interventional

Control:Diabetes Pilot Study I

NCT04158921
Conditions
Insulin Treated Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 1
Interventions
Control:Diabetes mobile app
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Diabetes Mellitus, Type 1
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut • Minneapolis, Minnesota
Conditions
Type 1 Diabetes (T1D)
Interventions
BREATHE-T1D, HealthEd-T1D
Behavioral
Lead sponsor
Children's National Research Institute
Other
Eligibility
13 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Aurora, Colorado • Washington D.C., District of Columbia